Other than having high blood pressure, I am healthy, eat a Mediterranean-style diet, and exercise most days. Since 2021, I have been taking one tab of amlodipine/valsartan daily with blood pressure ...

Swiss pharma giant Novartis has expressed its satisfaction at a decision by the US Court of Appeals for the Federal Circuit ...

Novartis, an innovative medicines company, announced that the company is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto ...

In our Case of the Week, the Federal Circuit revived Novartis’s US Patent No. 8,101,659 by reversing the district court’s decision which found the patent invalid for lack of written description. The ...

Novartis (NYSE:NVS) said the U.S. Court of Appeals for the Federal Circuit has upheld the company's U.S. combination patent for its blockbuster cardiac drug Entresto, also known as ...

Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto® (sacubitril/valsartan) combination patent. We ...

In a pivotal decision Friday, the Federal Circuit revived a key patent for Novartis' blockbuster heart failure drug Entresto, ...

The U.S. Court of Appeals for the Federal Circuit (CAFC) today issued a precedential decision reversing a district court’s ...

As the pharmaceutical sector continues to grow, the group is strategically positioning Globalpharma to capitalise on emerging ...

The momentum for 2025 builds on the success of 2024, which has seen the launch of several innovative products. These include ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Sacubitril and Valsartan (Entresto, Neparvis, Uperio, LCZ696, Vymada, ...